Target Product Profile for Next-generation Tuberculosis Drug-Susceptibility Testing at Peripheral Centres

In an effort to foster and achieve universal access to TB diagnostics and inform research and development (R&D) priorities for TB diagnostic tools, the World Health Organization (WHO) has released an updated target product profile (TPP) for next-generation tuberculosis drug-susceptibility (DST) testing for M. tuberculosis at peripheral centres.

This is an update of one of the high-priority TPPs published by WHO for new TB diagnostics in light of several advances in the TB diagnostics and treatment pipelines that have been observed. This updated TPP is intended to specify desire attributes of next-generation drug-susceptibility testing for M. tuberculosis and align the development of new interventions with evolving gaps and the needs of individuals and populations.